An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer

Trial Profile

An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs TRC 253 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2017 According to a TRACON Pharmaceuticals media release, dose escalation portion is expected to complete in the 1H 2018.
    • 17 Oct 2017 Planned End Date changed from 1 Sep 2018 to 1 Oct 2018.
    • 17 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top